In another phase I clinical trial where 16 HLA-A2+ NPC patients were vaccinated with autologous DCs pulsed with HLA-A2-restricted LMP2A peptides, the LMP2-specific T-cell response was improved in 9 of 16 patients, which correlated with a modest decrease in serum EBV DNA levels (187). This evidence concerns the gene PSMB9 and nasopharyngeal carcinoma.